{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113526","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.596905+00:00","generated_at":"2026-05-30T17:54:26.012333+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TuHURA reports H1 2024 net loss $10.1M, cash $12.3M; merger with Kintara on track for Q4 2024","bullets":["Net loss $10.1M for six months ended June 30, 2024; prior period loss $22.1M incl $16.2M IPR&D charge.","Cash $12.3M as of June 30, 2024, up from $3.7M at Dec 31, 2023; R&D expense $6.4M vs $4.0M YoY.","Convertible notes payable net $16.2M; derivative liability $2.0M; accumulated deficit $98.6M.","All-stock merger with Kintara expected to close Q4 2024; combined company to trade as HURA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113526","json":"https://secwatch.observer/filing/0000950170-24-113526.json","markdown":"https://secwatch.observer/filing/0000950170-24-113526.md","text":"https://secwatch.observer/filing/0000950170-24-113526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024113526/0000950170-24-113526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024113526/ktra-20241007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:54:26.012333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}